There is an urgent need to develop hand transplant programs in this country. To this end, the University of Michigan Hospital and Health Systems is developing such an interdisciplinary program. The Transplant Center would like to track the patient experience from pre-operative care through surgery and post-operative care. Detailed information will be collected from the patient medical records, including: Pre-operative screening, demographics, medications; Surgical information ; Post-operative inpatient and out-patient care; laboratory and other test results; physical assessments, psychological assessments and quality of life assessments.
Vascularized composite tissue allotransplantation (VCA) is the transplantation of multiple tissues containing skin, muscle, bone, joint, cartilage, nerve, tendon, vessels. VCA is useful for functional restoration of patients with severe tissue loss as encountered with massive burns, traumatic injuries, congenital anomalies, and following tumor resection. VCA, and specifically hand transplantation, combines the technical excellence of hand surgery/microsurgery with the complex multidisciplinary care rendered in modern solid organ transplantation. The technical demands of hand transplantation, enhanced donor antigen burden of the hand allograft, and complex psychosocial issues pertaining to the recipient account for much of the discrepancy between these 2 related fields. Detailed information will be collected from the patient medical records, including: Pre-operative screening, demographics, medications; surgical information ; post-operative inpatient and out-patient care; laboratory and other test results; physical assessments, psychological assessments and quality of life assessments. Specific outcomes will include allograft survival, allograft rejection, allograft functionality, and quality of life from transplant through 5 years.
Study Type
OBSERVATIONAL
University of Michigan
Ann Arbor, Michigan, United States
Allograft survival
Graft survival will be evaluated at transplant, days 14, then monthly in year 1, then yearly years 2-5
Time frame: Transplant through end of study (5 years)
Immunosuppression requirements
immunosuppression will be documented throughout study
Time frame: Transplant through end of study (5 years)
Allograft rejection
Skin and muscle biopsies will be performed days 14, then monthly in year 1, then yearly years 2-5. Donor specific antibody will also be measured at these timepoints
Time frame: Transplant through end of study (5 years)
Allograft Function
Outcomes questionnaires will be completed by patient at post-transplant 3, 6, 12 months, and every year thereafter up to 5 years
Time frame: Transplant through end of study (5 years)
Quality of life
SF-36 survey results will be collected before transplant and at various time points post transplant
Time frame: Transplant through end of study (5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.